{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:26:13Z","timestamp":1761989173741},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.cjca.2018.01.016","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T14:11:41Z","timestamp":1517407901000},"page":"565-574","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Genetic Link Between Diabetes and Atherosclerosis"],"prefix":"10.1016","volume":"34","author":[{"given":"Stephanie","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hertzel","family":"Gerstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2018.01.016_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11892-012-0268-5","article-title":"Glycemic control and cardiovascular disease: what's a doctor to do?","volume":"12","author":"Kishore","year":"2012","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.cjca.2018.01.016_bib2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib4","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib5","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib8","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/sim.3034","article-title":"Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology","volume":"27","author":"Lawlor","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ng.2383","article-title":"Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes","volume":"44","author":"Morris","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease","volume":"45","author":"Deloukas","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ng.3406","article-title":"An atlas of genetic correlations across human diseases and traits","volume":"47","author":"Bulik-Sullivan","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.atherosclerosis.2015.05.033","article-title":"Genetic variants primarily associated with type 2 diabetes are related to coronary artery disease risk","volume":"241","author":"Jansen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2018.01.016_bib15","doi-asserted-by":"crossref","first-page":"341ra376","DOI":"10.1126\/scitranslmed.aad3744","article-title":"A\u00a0genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease","volume":"8","author":"Scott","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib16","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/ng.3943","article-title":"Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease","volume":"49","author":"Zhao","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib18","doi-asserted-by":"crossref","first-page":"e7325","DOI":"10.1136\/bmj.e7325","article-title":"Use of Mendelian randomisation to assess potential benefit of clinical intervention","volume":"345","author":"Burgess","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2018.01.016_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/CIRCULATIONAHA.109.865444","article-title":"Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms","volume":"121","author":"Sofat","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.01.016_bib20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u201cMendelian randomization\u201d: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cjca.2018.01.016_bib22","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ije\/dyw088","article-title":"Selecting instruments for Mendelian randomization in the wake of genome-wide association studies","volume":"45","author":"Swerdlow","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cjca.2018.01.016_bib23","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg777","article-title":"Patterns of linkage disequilibrium in the human genome","volume":"3","author":"Ardlie","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ng1333","article-title":"Assessing the impact of population stratification on genetic association studies","volume":"36","author":"Freedman","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1211\/jpp.62.02.0002","article-title":"Methodological and statistical issues in pharmacogenomics","volume":"62","author":"Peters","year":"2010","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.cjca.2018.01.016_bib27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cjca.2018.01.016_bib28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/ije\/dyw127","article-title":"Commentary: Two-sample Mendelian randomization: opportunities and challenges","volume":"45","author":"Lawlor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cjca.2018.01.016_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/ATVBAHA.116.306256","article-title":"Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus","volume":"37","author":"Yahagi","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2018.01.016_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12933-016-0431-4","article-title":"Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice","volume":"15","author":"Avogaro","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cjca.2018.01.016_bib32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2337\/diacare.26.5.1589","article-title":"New insights on oxidative stress and diabetic complications may lead to a \u201ccausal\u201d antioxidant therapy","volume":"26","author":"Ceriello","year":"2003","journal-title":"Diabetes Care"},{"issue":"suppl 2","key":"10.1016\/j.cjca.2018.01.016_bib33","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.2337\/dc11-s220","article-title":"Hypoglycemia and cardiovascular risks","volume":"34","author":"Frier","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2018.01.016_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1172\/JCI10762","article-title":"Insulin resistance and cardiovascular disease","volume":"106","author":"Ginsberg","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2018.01.016_bib35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib39","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2018.01.016_bib40","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib41","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.cjca.2018.01.016_bib42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/dme.12885","article-title":"Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials","volume":"33","author":"Seidu","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib43","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(14)60611-5","article-title":"Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial","volume":"384","author":"Gerstein","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib44","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib45","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib46","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.01.016_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12933-017-0610-y","article-title":"Updates on cardiovascular outcome trials in diabetes","volume":"16","author":"Schnell","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cjca.2018.01.016_bib49","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.jacc.2012.02.043","article-title":"Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study","volume":"59","author":"Benn","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.01.016_bib50","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization","volume":"318","author":"Emdin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2018.01.016_bib51","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.cjca.2018.01.016_bib53","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/eurheartj\/ehv083","article-title":"Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease","volume":"36","author":"Ross","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.01.016_bib54","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1038\/ncomms8060","article-title":"A\u00a0Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease","volume":"6","author":"Ahmad","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2018.01.016_bib55","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1212\/WNL.0000000000004173","article-title":"Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes: Mendelian randomization study","volume":"89","author":"Larsson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2018.01.016_bib56","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib58","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.01.016_bib59","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.01.016_bib60","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib61","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2018.01.016_bib62","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fphar.2017.00372","article-title":"Statins and new-onset diabetes mellitus: LDL receptor may provide a key link","volume":"8","author":"Yu","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cjca.2018.01.016_bib63","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1161\/ATVBAHA.114.304131","article-title":"Apolipoprotein A-I increases insulin secretion and production from pancreatic beta-cells via a G-protein-cAMP-PKA-FoxO1-dependent mechanism","volume":"34","author":"Cochran","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2018.01.016_bib64","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.2337\/db16-0668","article-title":"Impact of Perturbed Pancreatic beta-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism","volume":"65","author":"Cochran","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.cjca.2018.01.016_bib65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2337\/db11-1341","article-title":"Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired beta-cell function","volume":"61","author":"Kruit","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.cjca.2018.01.016_bib66","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.2337\/db11-0081","article-title":"Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules","volume":"60","author":"Kruit","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.cjca.2018.01.016_bib67","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s00125-010-1691-2","article-title":"Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice","volume":"53","author":"Kruit","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.cjca.2018.01.016_bib68","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ng.3913","article-title":"Association analyses based on false discovery rate implicate new loci for coronary artery disease","volume":"49","author":"Nelson","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2018.01.016_bib69","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2018.01.016_bib70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2018.01.016_bib71","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib72","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2018.01.016_bib73","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/dc17-1464","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years","volume":"41","author":"de Carvalho","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2018.01.016_bib74","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.01.016_bib75","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2018.01.016_bib76","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2013.01.007","article-title":"Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy","volume":"227","author":"Bertolini","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2018.01.016_bib77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00109-005-0019-z","article-title":"Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing","volume":"84","author":"Humphries","year":"2006","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.cjca.2018.01.016_bib78","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2007.12.024","article-title":"Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors","volume":"200","author":"Alonso","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2018.01.016_bib79","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1161\/01.ATV.20.9.e41","article-title":"Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype","volume":"20","author":"Bertolini","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2018.01.016_bib80","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/db17-0173","article-title":"Familial hypercholesterolemia and type 2 diabetes in the old order Amish","volume":"66","author":"Xu","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.cjca.2018.01.016_bib81","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2018.01.016_bib82","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa0706728","article-title":"Polymorphisms associated with cholesterol and risk of cardiovascular events","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.01.016_bib83","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/MED.0000000000000230","article-title":"Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future","volume":"23","author":"Burgess","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.cjca.2018.01.016_bib84","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","article-title":"Mendelian randomization in cardiometabolic disease: challenges in evaluating causality","volume":"14","author":"Holmes","year":"2017","journal-title":"Nat Rev Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X18300199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X18300199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:27:14Z","timestamp":1668695234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X18300199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0828282X18300199"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2018.01.016","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Genetic Link Between Diabetes and Atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2018.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}